<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CARVEDILOL</span><br/>(car-ve-di'lol)<br/><span class="topboxtradename">Coreg, </span><span class="topboxtradename">Kredex <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification"> alpha- and beta-adrenergic antagonist</span>; <span class="classification">antihypertensive</span><br/><b>Prototype: </b>Propanolol HCl<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>3.125 mg, 6.25 mg, 12.5 mg, 25 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Adrenergic receptor blocking agent that combines selective alpha activity and nonselective beta-adrenergic blocking actions.
         Both activities contribute to blood pressure reduction. Peripheral vasodilatation and, therefore, decreased peripheral resistance
         results from alpha<sub>1</sub>-blocking activity of Coreg. It is 35 times more potent than labetalol in lowering blood pressure.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>An effective antihypertensive agent reducing BP to normotensive range and useful in managing some angina, dysrhythmias, and
         CHF by decreasing myocardial oxygen demand and lowering cardiac work load.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Management of essential hypertension, CHF, in conjunction with other heart failure medications, left ventricular dysfunction
         post MI.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Patients with class IV decompensated cardiac failure, bronchial asthma, or related bronchospastic conditions (e.g., chronic
         bronchitis and emphysema), second- and third-degree AV block, cardiogenic shock or severe bradycardia; pregnancy (category
         C), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients on MAOI agents, diabetes, hypoglycemia; patients at high risk for anaphylactic reaction, peripheral vascular disease,
         hepatic impairment. Safety and efficacy in patients 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">CHF</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 3.125 mg b.i.d. times 2 wk, may double dose q2wk as tolerated up to 25  mg b.i.d. if or 50 mg b.i.d. if &gt;85 kg<br/><br/><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 6.25 mg b.i.d., may increase by 6.25 mg b.i.d. to max of 50 mg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food to slow absorption and minimize risk of orthostatic hypotension.</li>
<li>Dose increments should be made at 7- to 14-day intervals.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Increased sweating, fatigue, chest pain, pain, arthralgia. <span class="typehead">CV:</span> Bradycardia, hypotension, syncope, hypertension, AV block, angina. <span class="typehead">GI:</span> Diarrhea, nausea, abdominal pain, vomiting. <span class="typehead">Respiratory:</span> Sinusitis, bronchitis. <span class="typehead">Hematologic:</span> Thrombocytopenia, <span class="typehead">Metabolic:</span> Hyperglycemia, weight increase, gout. <span class="typehead">CNS:</span>
<span class="speceff-common">Dizziness,</span> headache, paresthesias. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Rifampin</b> significantly decreases <b>carvedilol</b> levels; <b>cimetidine</b> may increase <b>carvedilol</b> levels; <b>clonidine,</b>
<b>reserpine,</b>
<span class="classification">mao inhibitors</span> may cause hypotension or bradycardia; <b>carvedilol</b> may increase <b>digoxin</b> levels and may enhance hypoglycemic effects of <b>insulin</b> and oral hypoglycemic agents, may enhance the effects of <span class="classification">antihypertensives</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract, 2535% reaches the systemic circulation. <span class="typehead">Peak:</span> Antihypertensive effect 714 d. <span class="typehead">Distribution:</span> &gt;98% protein bound. <span class="typehead">Metabolism:</span> Metabolized in the liver by CYP2D6 and CYP2C9 enzymes. <span class="typehead">Elimination:</span> Primarily eliminated via the bile through the feces. <span class="typehead">Half-Life:</span> 710 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness which is indicated by lessening of S&amp;S of CHF and improved BP control.</li>
<li>Lab tests: Monitor liver function tests periodically; at first sign of hepatic toxicity (see Appendix F) stop drug and notify
            physician.
         </li>
<li>Monitor for worsening of symptoms in patients with PVD.</li>
<li>Monitor digoxin levels with concurrent use; plasma digoxin concentration may increase.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not abruptly discontinue taking this drug.</li>
<li>You may experience dizziness or faintness, as a risk of orthostatic hypotension.</li>
<li>Do not engage in hazardous activities while experiencing dizziness.</li>
<li>If you have diabetes, the drug may increase effects of hypoglycemic drugs and mask S&amp;S of hypoglycemia.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>